文献速递妇科生殖医学

新辅助化疗后冷刀锥切用于IB2-IIA1期宫颈癌保留生育功能初探

Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study.
PubMed 文献 · Fertil Steril · 2020-10-20

该试点研究纳入25例小于40岁、2018 FIGO IB2-IIA1期且肿瘤大于2cm的宫颈癌患者,先行新辅助化疗, responsive者行冷刀锥切。13例适合保留生育,临床总缓解率84.5%, optimal病理反应率69.1%,中位随访37个月;3例尝试妊娠中2例自然妊娠。结论支持该保守治疗方案的可行性。

要点

  • IB2-IIA1期大于2cm宫颈癌患者,新辅助化疗后冷刀锥切可行。
  • 临床总缓解率84.5%,optimal病理反应率69.1%。
  • 保留生育组中位随访37个月,妊娠率66.7%。

核心结论

  • 该试点研究支持新辅助化疗后冷刀锥切作为IB2-IIA1期宫颈癌的保守治疗,肿瘤学结局与相同分期宫颈切除术相似,且可能改善产科结局。

研究设计与样本

  • 试点研究,2014至2018年纳入25例小于40岁、2018 FIGO IB2-IIA1期且肿瘤大于2cm的宫颈癌患者。

主要发现

  • 25例中13例适合保留生育治疗;临床总缓解率84.5%(11/13)。
  • 1例疾病稳定后行根治性手术仍存活;1例疾病进展15个月后死亡。
  • optimal病理反应率69.1%;保留生育组中位随访37个月(范围18-76)。
  • 保留生育组中1例锥切后12个月肝转移,仍存活无疾病证据。
  • 9例可评估妊娠者中3例尝试受孕,2例自然妊娠,妊娠率66.7%。

临床怎么用

  • 对小于40岁、IB2-IIA1期且肿瘤大于2cm、强烈要求保留生育的宫颈癌患者,可考虑新辅助化疗后冷刀锥切的保守策略。

局限性

  • 试点研究样本量小(25例),仅13例适合保留生育,产科结局评估例数更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate feasibility of neoadjuvant chemotherapy (NACT) followed by cold-knife conization (CKC) in patients with 2018 FIGO stage IB2-IIA1 cervical cancer who desired to maintain fertility. DESIGN: Pilot study of conization after chemotherapy in stage IB2-IIA1 >2 cm cervical cancer. SETTING: University hospital. PATIENT(S): From 2014 to 2018, 25 patients, <40 years of age, were enrolled. INTERVENTIONS(S): After laparoscopic pelvic lymph-node assessment, NACT with cisplatin/paclitaxel q21 was administered to eligible patients. Responsive patients were treated with CKC. MAIN OUTCOME MEASURE(S): Obstetrical outcome: pregnancy rate. Oncologic outcome. RESULT(S): Thirteen out of 25 patients were eligible for fertility-sparing treatment. Oncologic outcome: The clinical overall response rate was 84.5% (11 out of 13 patients). One patient achieved stable disease, was managed by radical surgery, and is still alive; another one experienced progression of disease and died after 15 months. The optimal pathologic response was 69.1%. In the setting of fertility preservation patients, the median follow-up was 37 months (range 18-76). In this group we registered one distant recurrence, 12 months after CKC, in the liver; the patient is still alive and without evidence of disease. Obstetrical outcome: Among the nine patients amenable, three tried to conceive, and two spontaneous pregnancy occurred a few months after the end of treatment, for a pregnancy rate of 66.7%. CONCLUSION(S): This pilot study supports the feasibility of CKC after NACT as conservative treatment in stage IB2-IIA1 cervical cancer, with oncologic outcomes similar to those reported for trachelectomy in the same stage and with potential benefits in terms of obstetrical outcomes. CLINICAL TRIAL REGISTRATION NUMBER: NCT02323841.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. de Vincenzo R, Ricci C, Fanfani F, et al. Neoadjuvant chemotherapy followed by conization in stage IB2-IIA1 cervical cancer larger than 2 cm: a pilot study. Fertil Steril. 2020. PMID: 33092819. doi:10.1016/j.fertnstert.2020.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。